Vadim Anatolievich Merkulov has a total of 242 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    mRNA vaccines for the prevention of infectious diseases: A review of international experience in evaluating efficacy and safety based on clinical trial results

    by A. Yu. Butirskiy, A. S. Korovkin, D. V. Gorenkov, V. A. Merkulov, А. Ю. Бутырский, А. С. Коровкин, Д. В. Горенков, В. А. Меркулов

    INTRODUCTION. The mRNA platform technology for creating vaccines against infectious diseases was introduced into clinical practice during the COVID-19 pandemic; however, the accumulated experience of clinical use of mRNA vaccines requires systematization in relation to other infectious diseases. Therefore, summarizing data on the efficacy and safety of such mRNA vaccines in controlled clinical trials is relevant for substantiating approaches to the regulatory evaluation of immunobiological medicinal products of this class. AIM. To review the results of clinical trials of mRNA vaccines for the prevention of respiratory syncytial virus infection (RSV infection), cytomegalovirus infection (CMV infection), seasonal influenza, Zika fever, and rabies to summarize data on their efficacy and safety, identifying the limitations associated with the use of surrogate endpoints and sample size. DISCUSSION. The authors analyzed publications in PubMed, eLIBRARY.RU and records in ClinicalTrials.gov describing the results of controlled clinical trials of mRNA vaccines for the prevention of infectious diseases (excluding COVID-19) from 2016 to 2026. Clinical efficacy was confirmed only for the mRNA-1345 vaccine against RSV infection: 83.7% (for episodes with 2 symptoms) and 82.4% (for episodes with 3 symptoms); the safety profile was considered satisfactory. For mRNA vaccines against seasonal influenza, a favorable safety profile and pronounced seroconversion in the hemagglutination inhibition assay were confirmed; the humoral immunity parameters were comparable to those of licensed vaccines. The mRNA-1647 vaccine against CMV infection, after a three-dose regimen, induced a durable immune response with the activation of T-cell immunity, along with a favorable safety profile. In a study of vaccines for the prevention of Zika fever (mRNA-1325, mRNA-1893), the presence of neutralizing antibodies (in a neutralization assay) after vaccination was demonstrated in participants with different baseline flavivirus serostatus; the safety profile was considered favorable. The mRNA vaccine CV7201 against rabies induced protective titers of virus-neutralizing antibodies in 71% of study participants after intradermal administration and in 46% after intramuscular administration; the incidence of local and systemic adverse events (AEs) was high (97% and 78%, respectively). Most studies were shown to have limitations associated with the assessment of efficacy using surrogate endpoints and an insufficient sample size to detect rare adverse events. CONCLUSIONS. The results of controlled clinical trials of mRNA vaccines for the prevention of RSV and CMV infection, seasonal influenza, Zika fever, and rabies demonstrated their potential efficacy and acceptable safety profile; however, the evaluation of most products is based on surrogate endpoints and small sample sizes, which are the main limitations of the conducted studies. The findings substantiate the need for further research using endpoints (clinical efficacy, surrogate markers) and post-marketing safety monitoring (primarily for local and systemic AEs).

  • Open Access

    Oligonucleotide-based medicinal products: A review of current regulatory requirements for preclinical studies

    by G. N. Engalycheva, R. D. Syubaev, A. A. Berchatova, O. V. Astapova, D. V. Goryachev, V. A. Merkulov, Г. Н. Енгалычева, Р. Д. Сюбаев, А. А. Берчатова, О. В. Астапова, et al.

    INTRODUCTION. Oligonucleotides represent a promising class of drugs with unique physicochemical properties, pharmacokinetic characteristics, mechanisms of action, and encouraging therapeutic potential. Due to the lack of a national Russian guideline and a guideline currently effective within the Eurasian Economic Union (EAEU), existing international regulatory requirements for the preclinical safety assessment of oligonucleotides were reviewed. AIM. To analyze regulatory documents and scientific and methodological sources addressing current approaches to the preclinical development of therapeutic oligonucleotides. DISCUSSION. Oligonucleotides represent an established class of medicinal products consisting of chemically synthesized compounds that are polymorphic in structure and mechanism of action, possessing highly specific pharmacological activity. The pharmacological action of oligonucleotides is based on the specific binding of synthetically modified RNA or RNA/DNA hybrids to target RNA sequences to alter RNA expression and/or subsequent protein expression. Oligonucleotides can vary by mechanism of action, structure, chemical modifications, size, sequence, delivery strategy, as well as by the presence or absence of other functional groups, such as small molecules, proteins, or antibodies. In terms of target and species specificity, these drugs occupy an intermediate position between small molecules and biologics. Currently, antisense oligonucleotides, small interfering RNAs, and aptamers are successfully utilized in clinical practice. Local guidelines for the preclinical safety assessment of oligonucleotides proposed by the Pharmaceuticals and Medical Devices Agency (PMDA), the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA) serve as an interim step prior to the release of the globally harmonized International Council for Harmonisation (ICH) S13 guideline, which is currently being developed by international regulators. In accordance with the Fundamental Scientific Research Program in the Russian Federation for the 2021–2030 period, which states the goal of creating technologies for silencing damaged genes using oligonucleotides, the development of a guideline for the preclinical studies of oligonucleotides is considered appropriate. CONCLUSIONS. Therapeutic oligonucleotides have a dual nature, combining the characteristics of small chemical molecules and highly specific biotechnological products. Since oligonucleotide development is a dynamically evolving scientific field, it is advisable to utilize a flexible, case-by-case approach when planning and conducting preclinical studies. This approach should account for chemical modification, mechanism of action, delivery method, and current scientific knowledge regarding the potential toxic effects of this drug class.

  • Open Access

    Criteria for the application of the platform approach for mRNA vaccines and gene therapy products in regulatory practice

    by N. S. Pokrovsky, E. V. Melnikova, V. A. Merkulov, Н. С. Покровский, Е. В. Мельникова, В. А. Меркулов

    INTRODUCTION. The platform approach, which involves the use of an unchanged manufacturing process and standardized quality control methods, is recognized by leading regulatory authorities, such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), as an effective tool for accelerating market entry of innovative products, namely mRNA vaccines and gene therapy products. In this context, the implementation of this concept is relevant for the Russian Federation and the countries of the Eurasian Economic Union (EAEU), as it would accelerate pharmaceutical development, optimize quality control and process validation, and improve regulatory review during the registration of such products. AIM. This study aimed to analyze international regulatory approaches to the application of platform technologies in the manufacturing and quality control of mRNA vaccines and gene therapy products based on viral vectors and genome editing systems, in order to provide a rationale for their implementation in the national legislation and regulatory documentation of the Russian Federation and the EAEU. DISCUSSION. An analysis of publications from 2015 to 2025 in the PubMed, Google Scholar, and eLIBRARY.ru databases, as well as official documents from regulatory authorities, including the FDA, the EMA, the World Health Organization (WHO), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the Medicines and Healthcare products Regulatory Agency, and the Pharmaceuticals and Medical Devices Agency (PMDA), addressing the application of platform technologies in the manufacturing and quality control of medicinal products, was performed. It was found that the regulatory documentation of the Russian Federation and the EAEU lacks criteria for applying the platform approach to mRNA vaccines and gene therapy products, which hinders the accelerated introduction of innovative personalized medicinal products into clinical practice. International regulatory approaches (FDA, EMA, PMDA) were shown to accelerate development and process validation, and reduce the scope of preclinical studies and clinical trials through the reuse of data on previously manufactured and approved products (including data on the manufacturing process and safety profiles for mRNA vaccines and gene therapy products). The main unresolved issues remain the amount of supporting data and the need for a first approved product before platform technology status can be granted. The need to develop unified regulatory requirements for relevant experience and process validation was substantiated, which would allow the benefits of the platform approach to be realized while maintaining a high level of safety and efficacy of medicinal products during regulatory review. CONCLUSIONS. The platform approach, based on an unchanged manufacturing process and standardized quality control methods, can accelerate pharmaceutical development, reduce the extent of preclinical studies and clinical trials, and optimize the regulatory review of mRNA vaccines and gene therapy products. To implement this approach in the Russian Federation and the EAEU, it is necessary to incorporate provisions into the regulatory documentation allowing the use of standardized modules within a single technological platform, which would accelerate the development and market launch of gene therapy products and personalized products, and increase their affordability.

  • Open Access

    Design Features of Nonclinical Studies for In Vivo Gene Therapy Medicinal Products. Part 2: Pharmacokinetic and Toxicological Studies

    by O. A. Rachinskaya, Е. В. Мельникова, V. A. Merkulov

    The article focuses on the specific design features of nonclinical studies (NCS) of in vivo gene therapy medicinal products which involve the administration of vectors with recombinant nucleic acids into the patient’s body for the correction of genetic disorders and treatment of oncological diseases. This work highlights the key aspects of conducting pharmacokinetic and toxicological studies, identified through the analysis of expert reports from global gene therapy medicinal products manufacturers. These aspects include dose selection and route of administration; identification of specific studies applicable to all in vivo gene therapy medicinal products and the justification of study lists for products using different types of vectors; as well as duration of studies and the selection of appropriate models to demonstrate product safety and to detect potential adverse effects associated with their use.


  • Open Access

    Clinical trials and post-marketing studies of anti-rabies monoclonal antibodies for post-exposure prevention: A review

    by A. Yu. Butirskiy, A. S. Korovkin, A. A. Movsesyants, V. A. Merkulov

    INTRODUCTION . Rabies is an invariably fatal disease having no adequate cure; in some cases it requires administration of rabies immunoglobulin combined with rabies vaccine. Given the supply constraints of rabies immunoglobulin derived from donor blood, research is underway worldwide to develop preparations based on neutralising monoclonal antibodies (mAbs), which are potentially relevant for the Russian healthcare system. AIM. This study aimed to perform a narrative review of the development, clinical trials, and post-marketing safety and efficacy studies of rabies monoclonal antibodies intended for post-exposure prophylaxis in combination with rabies vaccination. DISCUSSION . Currently, three rabies mAb drugs have been registered worldwide. Of them, two are manufactured in India (a recombinant human anti-rabies antibody; a combination drug of docaravimab and miromavimab) and one in China (ormutivimab). Preclinical studies of these drugs have confirmed their ability to neutralise the rabies virus, including wild strains. Clinical trials have established a favourable safety profile for these anti-rabies mAbs (adverse events are generally transient and self-resolving) and a lack of immune interference with administered rabies vaccines. Administration of all the above drugs did not change immune response to the complete course of anti-rabies vaccination, unlike human immunoglobulin preparations. On Day 42 (4 weeks after the last dose of rabies vaccine), virus-neutralising antibody titers reached 31.12 IU/mL for the recombinant human rabies antibody preparation and 122 IU/mL for docaravimab and miromavimab combination. Controlled clinical trials and post-registration studies of the recombinant human rabies antibody and docaravimab-miromavimab combination showed no rabies episodes in patients receiving post-exposure prophylaxis with the study drugs and the rabies vaccine. CONCLUSIONS . Anti-rabies mAb preparations are an effective and safe option for post-exposure rabies prophylaxis, confirmed by their worldwide use. Integrating these drugs into comprehensive patient care will help overcome the potential shortage of rabies immunoglobulins in the Russian Federation. When registering anti-rabies mAbs, key objectives are to assess cross-reactivity with human tissues ex vivo and confirm neutralising activity against viral isolates common in Russia and the neighbouring countries.

  • Open Access

    Design Features of Nonclinical Studies of In Vivo Gene Therapy Medicinal Products. Part 1: Pharmacological studies

    by O. A. Rachinskaya, Е. В. Мельникова, V. A. Merkulov

    Особенности дизайна доклинических исследований препаратов генной терапии in vivo. Часть 1: фармакологические исследования


  • Open Access

    Orthogonal approach and critical quality attributes for gene and cell therapy products

    by Екатерина В. Мельникова, Марина A. Водякова, Никита С. Покровский, Вадим A. Меркулов

    Introduction: Gene and cell therapy (GCT) products are revolutionizing medicine because they are made up of unique biological components like genetic material, viral vectors, and viable cells. However, their complexity necessitates rigorous quality control strategies to ensure efficacy, safety, and batch consistency. This manuscript explores the application of an orthogonal approach – employing multiple independent methods – to assess critical quality attributes, such as identity, potency, and purity of GCT products. Materials and Methods: To achieve the aim of our work, we analyzed 15 GCT products for 11 different types of diseases and reports of multiple regulatory agencies. Results: For cell-based therapies, identity is confirmed through genotypic, phenotypic, and morphological analyses, while potency is evaluated using functional assays tailored to the product’s mechanism of action, such as cell viability, differentiation status, or cytokine secretion. Viral vector-based therapies require characterization of structural integrity, transgene expression, and the ratio of full to empty capsids, employing techniques like dynamic light scattering (DLS), PCR, and ELISA. Conclusion: The paper highlights regulatory recommendations from the FDA, EMA, and WHO, emphasizing the need for validated assays during product release and stability testing. Case studies, including CAR-T cells and AAV-based therapies, illustrate the practical implementation of orthogonal methods. Challenges such as assay variability and the need for clinical correlation are discussed, underscoring the importance of assay development early in the product lifecycle. By integrating diverse analytical techniques, the orthogonal approach ensures comprehensive product characterization facilitating the translation of GCTs from research to clinical application.

  • Open Access

    Monoclonal antibodies: Development of universal (platform) methods for the assessment of high and low-molecular weight impurities

    by O. A. Vaganova, R. S. Smirnov, S. A. Lenin, K. S. Funtashev, A. A. Kostromskih, A. S. Peregudova, D. A. Kadykova, V. A. Merkulov

    INTRODUCTION. The development of unified techniques for quality control monoclonal antibodies (mAb) is one of the challenges for mAbs quality standardization.AIM. This study aimed to develop and analyse the possibility of using platform (universal) techniques for estimating the impurity content of high molecular weight compounds and fragments, non-glycosylated molecules in various mAbs by methods of size-exclusion high performance liquid chromatography (SE-HPLC) and capillary electrophoresis methods.MATERIALS AND METHODS. MAbs-containing medicinal products from 28 different international nonproprietary names of Russian and foreign origin. Studies by SE-HPLC were carried out on Agilent Technologies 1200 series instruments equipped with UV detectors, with data processed via OpenLab software. Capillary gel electrophoresis (CGE) was conducted under both reducing and non-reducing conditions using a PA 800 plus system (Beckman Coulter) with UV diode array detection, and Beckman 32Karat software.RESULTS. Universal sample preparation protocols and separation conditions were established and validated across 28 mAbs. Retention times and relative migration times of target compounds peaks were determined for each mAb. Comparative analysis demonstrated concordance between platform methods and manufacturers' proprietary methods. Validation of methods for determination of the content of high-molecular weight compounds in mAbs samples by the SE-HPLC method, fragments of mAbs and non-glycosylated variants of heavy chains of mAbs under reducing and non-reducing conditions by the CGE method was performed. The accuracy, precision, and sensitivity of the methods met the established requirements. The validation characteristics obtained for the SE-HPLC method were as follows: precision (RSD) of peak areas was no more than 0.4% for the monomer, up to 8% for aggregate groups, no more than 0.4% for total peak areas, and 0.02% for the relative peak area corresponding to the monomer. The method's linearity was confirmed within the concentration range of 0.5–120%, accuracy within 99.1–102.1%, and the limit of quantification (LOQ) was 0.1%. For the CGE method, the validation characteristics showed precision of no more than 1% for intact immunoglobulin content or heavy and light chain peaks, and no more than 1% for absolute migration times of main peaks. Linearity was confirmed from LOQ to 300% concentration range. The accuracy for both methods ranged from 97.6–103.7%, with LOQ values of 0.5% and 0.75%, respectively.CONCLUSIONS. The developed methods for assessing the purity are universal for unconjugated mAbs products. Their validation characteristics — including specificity, precision, limit of quantification, analytical range, linearity, and accuracy — meet all established acceptance criteria. These methods can be reliably implemented at any stage of the product lifecycle for this category of medicinal products.


  • Open Access

    Quality control programmes for induced pluripotent stem cell-derived medicinal products

    by Е. В. Мельникова, O. A. Rachinskaya, I. S. Semenova, V. A. Merkulov

    INTRODUCTION. Currently, there are no harmonised regulatory requirements for the quality control of human somatic cell therapy and tissue-engineered medicinal products that contain differentiated cells derived from induced pluripotent stem cells (iPSCs). This lack of uniform requirements underscores the need for approaches to developing quality control programmes and establishing critical quality attributes for iPSC-derived medicinal products within the Eurasian Economic Union (EAEU) regulatory framework.AIM. This study aimed to systematise global regulatory experience and EAEU regulatory requirements for the development and justification of quality control programmes for iPSC-derived medicinal products.DISCUSSION. Medicinal products derived from iPSCs are mainly used in the treatment of neurodegenerative, cardiovascular, and oncological diseases, diabetes, graft-versus-host disease, and eye diseases. Over the past decade, specific recommendations and requirements for the quality of clinical-grade iPSCs have been published by the Chinese Society for Stem Cell Research (CSSCR), the Japanese Ministry of Health, Labour, and Welfare (MHLW), the Global Alliance for iPSC Therapy (GAiT), and the European Bank of iPSC (EBiSC). The EAEU regulatory requirements for the quality of genetically modified cells have been in effect since 2025 (Chapter 32 of Decision No. 89 of the Council of the Eurasian Economic Commission “On Approval of the Rules for Assessment of Biological Medicines in the EAEU” of November 3, 2016). The list of critical quality attributes for clinical-grade iPSCs proposed by the GAiT generally corresponds to the EAEU regulatory framework and can be used in drawing up quality control programmes for iPSC-derived medicinal products in the Russian Federation and the EAEU. Quality control programmes for finished somatic cell therapy or tissue-engineered medicinal products derived from iPSCs should be based on the principle of quality attribute traceability from the starting material onwards. The production of iPSCs is a full-fledged production process that must comply with Good Manufacturing Practice (GMP) requirements for genetically modified cells. Specific quality controls for iPSCs should include tests for residual reprogramming vector DNA, markers of the undifferentiated state, and pluripotency as part of purity characterisation, identification, and potency evaluation, respectively.CONCLUSIONS. A quality control programme for a finished iPSC-derived medicinal product should correspond to the type of differentiated cells and take into account the indications for use. Critical quality considerations for iPSC characterisation include demonstrating the absence of contaminating undifferentiated cells or cells with new immunogenic epitopes and confirming the identity and genetic stability of iPSCs. The considered quality assessment approaches provide a basis for developing both quality control strategies for iPSC-derived medicinal products and specifications for marketing authorisation according to the EAEU requirements.